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Abstract
Purpose Medical oncology needs early identification of
patients that are not responding to systemic therapy. 18F-
Fluorodeoxyglucose (FDG) positron emission tomography
(PET) performed before and early during treatment has been
proposed for this purpose. However, the best way to assess
the change in FDG uptake between two scans has not been
identified. We studied cutoff thresholds to identify respond-
ing tumours as a function of the method used to measure
tumour uptake.
Methods The study included 28 metastatic colorectal cancer
(mCRC) patients who underwent 2 FDG PET/CT scans
(baseline and at day 14 of the first course of polychemo-
therapy). For 78 tumour lesions, 4 standardized uptake value
(SUV) indices were measured: maximum SUV (SUVmax)
and mean SUV in a region obtained using an isocontour
(SUV40 %), with each of these SUV normalized either by the
patient body weight (BW) or body surface area (BSA). The
per cent change and absolute change in tumour uptake be-
tween the baseline and the early PET scans were measured
based on these four indices. These changes were correlated to
the RECIST 1.0-based response using contrast-enhanced CT
at baseline and at 6–8 weeks on treatment.
Results The 78 tumours were classified as non-responding
(NRL, n058) and responding lesions (RL, n020). Receiver-
operating characteristic (ROC) curves characterizing the
performance in NRL/RL classification using early FDG
PET uptake had areas under the curve between 0.75 and
0.84, without significant difference between the indices. The
cutoff threshold in FDG uptake per cent change to get a 95 %
sensitivity of RL detection depended on the way uptake was
measured: −14 % (specificity of 53 %) and −22 % (specificity
of 64 %) for SUVmax and SUV40 %, respectively. Thresholds
expressed as absolute SUV decrease instead of per cent change
were less sensitive to the SUV definition: an SUV decline by
1.2 yielded a sensitivity of RL detection of 95 % for SUVmax
and SUV40 %. For a given cutoff threshold, the sensitivity was
the same whatever the normalization (by BSA or BW).
Conclusion A 14 % drop of tumour FDG SUVmax, 22 %
drop of SUV40 % or 1.2 drop of SUVmax or SUVmean after
one single course of polychemotherapy predicts objective
response in mCRC lesions with a high sensitivity, potentially
allowing the early identification of non-responding patients.
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Introduction
18F-fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) was proposed for the early assessment of
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treatment response in cancer patients almost 20 years ago
[1, 2]. Since then, the potential of FDG PET for cancer
patient monitoring has been well established [3]. In that
context, the usefulness of quantitation of FDG uptake in
tumours compared to a visual analysis only has also been
suggested [4, 5]. Yet, there is currently no validation of the
best method to be used to measure FDG uptake in tumours
and the cutoff thresholds of decline in uptake to consider for
identifying responding tumours [6–8]. Practical considera-
tions have led to a widespread use of the standardized
uptake value (SUV) as a metric for characterizing tumour
uptake. However, many methods can be used to estimate
SUV, mostly varying in the way SUV is normalized (to body
mass, lean body mass or body surface area) and in the
tumour region of interest (ROI) used to measure SUV (single
voxel, fixed number of voxels, tumour-dependent number of
voxels chosen either manually or semiautomatically). It is
now obvious that standardizing quantitative procedures and
quality control is required to make the most of 18FDG PET in
the context of therapy monitoring [9, 10]. As early as 1999,
the European Organization for Research and Treatment of
Cancer (EORTC) published recommendations on the mea-
surement of tumour response using 18FDG PET, based on
the use of SUV [11]. These recommendations were derived
from an extensive review of the limited data available in the
literature at that time. The recommended approach has been
used in a large number of studies since then. However, as the
recommendations did not include any strict description of the
way SUV had to be measured, the so-called EORTC 1999
criteria most often only refer to the cutoff thresholds to be used
for distinguishing between progressive metabolic disease
(PMD), stable metabolic disease (SMD), partial metabolic
response (PMR) and complete metabolic response (CMR).
The aim of our study was to investigate the relevance of the
recommended cutoff thresholds as a function of the method




Twenty-eight patients (mean age 62.8 years, range 23–
83 years) with metastatic colorectal cancer treated at the
Institut Jules Bordet, Brussels, Belgium, were included in
the study. All patients were prospectively recruited, as part
of a prospective clinical trial on a larger cohort of patients
for assessing the role of early FDG PET/CT as a predictor of
the RECIST-based morphological response to chemothera-
py in metastatic colorectal cancer patients [12]. The study
was approved by the Ethics Committee of the Institut
Bordet and registered in clinicaltrials.gov under number
NCT00741481. Written informed consent was obtained from
all patients. All patients presented advanced metastatic colo-
rectal cancer deemed to be treated by chemotherapy. Chemo-
therapy involved FOLFOX (19 patients), FOLFIRI (9
patients) and capecitabine (1 patient) as first- (20) or second-
line (9) treatments. The mean number of lesions per patient
was 3 (range 1–8). A total of 78 lesions were analysed (3
primary, 49 in the liver, 8 in the lungs, 10 in the peritoneum
and 8 at other various locations).
Imaging protocols
Each patient had a first helical diagnostic CT with or without
IV contrast injection (depending on the evaluated lesion) 8 days
(range 0–23 days) on average before the first FDG PET/CT,
and a second CT scan after 5–8 weeks on therapy, or sooner in
case of clinical suspicion of progression. Axial slice thickness
was 3 or 5 mm, depending on the scanner used for the CT.
Each patient also underwent a baseline FDG PET/CT
scan just before the start of chemotherapy (day 0) and a
follow-up scan at day 14 (mean±1 SD013.7±2.7). Patient
preparation, imaging and reconstruction protocols were kept
constant for serial scans in the same patient. The FDG PET/
CT images were obtained using a GE Discovery LS system,
60 min (range 53–87 min) after injection of 4 MBq/kg. For
all patients included in the study, the post-injection time
between the baseline and early PET did not differ by more
than 15 min. PET images were reconstructed with the built-
in GE Advance software, using the ordered subset expecta-
tion maximization (OSEM) algorithm with 2 iterations and
28 subsets, and a 5.45 mm full-width at half-maximum
(FWHM) Gaussian post-filtering. The images were cor-
rected for attenuation based on the CT and for scatter. The
CT was performed with a 4-slice multidetector helical scan-
ner (Lightspeed, GE Medical Systems). The tension was
120 kV, and the range of currents was set from 30 to
200 mA. The actual current within this range was deter-
mined by the AutomA, an algorithm from GE that modifies
the intensity during the acquisition depending on a noise
index and the attenuation information given by the scout
view. The noise index used for this low-dose CT was 25.
The other parameters were 0.5 s per CT rotation, a pitch of
1.5 and a table speed of 15 mm/rotation. The matrix of CT
images was 512×512 (0.98×0.98 mm pixel size) with a
5-mm slice thickness. The PET volumes (128×128 pixels
of 3.91×3.91 mm, 4.25-mm slice thickness) and the CT
volumes were systematically coregistered using the GE soft-
ware (LightSpeedAppsct_dst_dls_1.7_R2.9N.IRIX646.5).
CT image interpretation
Target lesions were initially identified by a senior radiologist
and two nuclear medicine physicians in a joint reading
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session. Only FDG-avid lesions clearly individualized on
both baseline PET and diagnostic CT and that had a minimal
diameter of 15 mm on the baseline diagnostic CT were
considered as target lesions. A lesion-by-lesion analysis
was performed. CT was interpreted according to RECIST
criteria 1.0, as follows [13]:
– Complete response was defined as the disappearance of
the target lesion with no evidence of tumour elsewhere.
– Partial response was defined as at least a 30 % reduction
in the tumour dimension, where the tumour dimension
was defined as the single longest dimension of the
tumour in the transaxial plane.
– Progressive lesion was defined as an increase of at least
20 % in the tumour dimension.
– A stable lesion was a lesion that was visible but did not
meet the partial response or progressive lesion criteria.
For these stable lesions, confirmation of stable disease
status was obtained by an additional CT scan (i.e. a third
CT scan) after 6–8 more weeks.
Complete response and partial response were considered
as responding lesions (RL), while progressive lesions and
stable lesions were considered as non-responding lesions
(NRL).
PET image quantitation
To compare PET scans acquired before and during therapy,
the images were converted in SUV units. Two normalizations
were considered to derive the SUV images:
– Normalization by the injected activity corrected for
radioactive decay and divided by the body surface area
(BSA). The BSA (m2) was given by BSA00.00718×
W0.425×H0.715, where W is the patient weight (kg) and
H is the patient’s height (cm), as recommended by the
EORTC [11, 14].
– Normalization by the injected activity corrected for
radioactive decay and divided by the patient’s body
weight (BW), as most commonly used in clinical
practice.
For each patient, each target tumour and each SUV
normalization, two SUV indices frequently used in clinical
practice were measured in each of the two PETscans available
for the patient (baseline and during therapy):
– Maximum SUV (SUVmax) in the tumour, corresponding
to a 1-voxel ROI.
– Mean SUV in the tumour in a 3-D ROI obtained using
an isocontour set at 40 % of the SUVmax in the tumour
(SUV40 %). This region and the number of voxels it
included could thus be different for the baseline and
early PET scans.
From these measurements, eight indices characteriz-
ing the change in tumour uptake between the baseline
and the early PET scans were derived. Four indices,
namely ΔSUVmax_BSA, ΔSUV40 %_BSA, ΔSUVmax_BW and
ΔSUV40 %_BW, corresponded to per cent changes in SUV
between the baseline and early PET scans, with:




X corresponded to the two SUV measurement methods
(max or 40 %) and Y corresponded to the two normalization
methods (BSA or BW).
Four indices, diffSUVmax_BW, diffSUV40 %_BW, diffSUV-
max_BSA and diffSUV40 %_BSA, measured the absolute change in
SUV between the baseline and early PET scans, with:
diffSUVX Y ¼ SUVX Yearly  SUVX Ybaseline
Receiver-operating characteristic curve analysis
To determine how well the eight indices characterizing the
change in tumour uptake could distinguish between RL and
NRL, nonparametric receiver-operating characteristic
(ROC) curve analysis was performed using the ROCKIT
s o f t w a r e ( h t t p : / / r a d i o l o g y . u c h i c a g o . e d u / ?
q0MetzROCsoftware). By considering the RL and NRL
classification given by the RECIST criteria, ROC curves
were plotted for ΔSUVmax_BSA, ΔSUV40 %_BSA,
ΔSUVmax_BW, ΔSUV40 %_BW, di ffSUVmax_BW,
diffSUV40 %_BW, diffSUVmax_BSA and diffSUV40 %_BSA, by
varying a cutoff threshold T: ifΔSUVX_Yor diffSUVX_Y was
less than T, the tumour was classified as RL, while if
ΔSUVX_Y or diffSUVX_Y was equal to or greater than T, it
was classified as NRL. The ROC curves were obtained by
plotting the sensitivity of detecting RL as a function of [1
minus the specificity].
The cutoff thresholds corresponding to a 95 % sensitivity
of detecting RL were deduced from the ROC curves of each
ΔSUVX_Y or or diffSUVX_Y index, and the corresponding
specificity values were determined. The thresholds yielding
a negative predictive value (NPV) of 95 % were also deter-
mined for each ΔSUVX_Y and diffSUVX_Y index and the
corresponding positive predictive values (PPV) were deduced.
Results
Tumour classification
According to RECIST, the 78 tumours were classified as 20
partial responses, 44 stable lesions and 14 progressive
lesions. This corresponds to 20 RL and 58 NRL.
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Performance of the eight indices to identify RL
Figure 1 shows the eight ROC curves representing the
performance of the eight indices to distinguish between
RL and NRL when considering all lesions. The areas under
the curves (AUC) are summarized in Table 1. None of the
AUC was significantly different from the others (nonpara-
metric paired tests with α00.05) [15].
Cutoff thresholds of FDG uptake change for identifying RL
Table 2 gives the cutoff thresholds and corresponding sensi-
tivity, specificity, accuracy, NPV and PPV for the different
indices. Four sets of results are shown: those corresponding to
setting the cutoff threshold to 15 or 25 % as recommended by
the EORTC as well as the results obtained when aiming at a
95 % sensitivity for detecting RL or when aiming at a 95 %
NPV. In these latter cases, values for the four indices normal-
ized by BSA are not included as they always differ by less
than 2 % from the corresponding indices normalized by BW.
Table 3 shows the 2×2 arrays describing the agreement
between SUV40 %_BW and SUVmax_BW, when setting the
cutoff threshold to 15 % (left array) and 25 % (right array).
The number of disagreements was about the same whatever
the cutoff threshold (18/78 for a threshold set to 15 % and
17/78 for a threshold set to 25 %).
Discussion
We tested the relevance of the cutoff thresholds of
treatment-induced FDG uptake change to characterize the
early tumour response to (poly)chemotherapy on a lesion-
by-lesion basis in a prospective cohort of metastatic colo-
rectal cancer patients. The oncological rationale behind ear-
ly response assessment is the timely identification of NRL
and/or patients so that inappropriate treatments can be rap-
idly replaced or adjusted. Doing this the highest care should
be provided in order not to falsely exclude patients from a
potentially beneficial treatment modality. Therefore, our
testing aimed at 95 % sensitivity and NPV for prediction
of response.
To perform such an investigation, we needed to have an
FDG PET-independent way to distinguish RL and NRL. In
our protocol, the objective lesion size-based tumour re-
sponse according to RECIST, derived from follow-up CT
scans performed at 6–8 weeks on therapy, was used as the
reference of response. As a result, our study actually inves-
tigated on a lesion-by-lesion basis how appropriate FDG
PET-based metabolic criteria were for predicting the size-
based tumour response later seen using the CT scan. We also
investigated whether the thresholds to be used depended on
the way SUV was calculated.
Our results (Fig. 1 and Table 1) first suggest that all SUV
indices considered in this study yielded similar performance
of RL/NRL classification, since the ROC curves were sim-
ilar with non-significant differences between the AUC. This
means that neither the normalization used for calculating the
SUV (BSA or BW), nor the way uptake was measured
(using SUVmax or SUV40 %) nor the way change in uptake
was evaluated (per cent change or absolute change) did
impact the classification performance. FDG PET images
therefore include robust quantitative information for identi-
fying RL. The index that most accurately reflects such
Fig. 1 a ROC curves corresponding to the ΔSUVmax_BSA,
ΔSUV40 %_BSA, ΔSUVmax_BW and ΔSUV40 %_BW indices used to dis-
criminate between RL and NRL. b ROC curves corresponding to the
diffSUVmax_BSA, diffSUV40 %_BSA, diffSUVmax_BW and diffSUV40 %_BW
indices used to discriminate between RL and NRL. Red points show the
operating points for which a 95 % sensitivity is achieved with the
maximum specificity
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information still needs to be identified, and our results
suggest that SUVmax and SUVmean are two candidates that
performed well in our context. However, our results also
show that the cutoff threshold yielding a 95 % sensitivity for
detecting RL is substantially different when using SUVmax
(−14 %) or SUVmean (−21 or −22 % depending on the SUV
normalization) (Table 2). All these values are consistent
with the range (−25 to −15 %) that the EORTC recommen-
ded when assessing the treatment response after a single
cycle of chemotherapy. Yet, an important finding is that
using a given cutoff threshold the sensitivity of detecting
RL depends on the way SUV is measured. For instance,
considering the lower bound of the range recommended by
the EORTC (15 % decline in SUV for establishing RL),
sensitivity of detecting RL is 95 % with ΔSUV40 %_BW (for
a 53 % specificity, NPV of 97 %) but only 80 % with
ΔSUVmax_BW (for a 53 % specificity, NPV of 89 %). Con-
sidering the upper range recommended by the EORTC
(25 % decline in SUV for establishing RL), sensitivity of
detecting RL is 90 % with ΔSUV40 %_BW (for a 64 %
specificity, NPVof 95 %) but only 65 % with ΔSUVmax_BW
(for a 67 % specificity, NPV of 85 %). Considering cutoff
thresholds between 15 and 25 % for any ΔSUVX_Y index
always yielded an NPVequal to or greater than 85 %, which
confirms the relevance of the EORTC criteria for assessing
tumour response. Yet, using SUVmean, higher cutoff values
should be used to yield NPV similar to those obtained with
SUVmax. Depending on the context of patient management,
the target sensitivity, specificity, NPV or PPV may differ
from the one considered in our work. Yet, based on our
results, it is expected that the threshold to be used to reach
the target values will depend on the way the SUV is mea-
sured. In this work, we only studied SUVmax and SUV40 %,
as they are frequently used in routine daily practice, but it is
likely that other thresholds would be found “optimal” (in
terms of targeting a sensitivity or NPV values) if other SUV
definitions were used.
Although change is SUV is most often evaluated in terms
of per cent decline, we also studied whether analysing
absolute change in SUV units instead of per cent change
Table 1 Areas under the ROC
curves (±1 standard deviation) as
a function of the index used to
discriminate RL and NRL when
considering all 78 lesions
max_BW 40 %_BW max_BSA 40 %_BSA




baseline 0.79±0.06 0.84±0.05 0.78±0.06 0.83±0.05
Table 2 Cutoff threshold and corresponding sensitivity, specificity, NPVand PPV for detecting RL using FDG PET. In total, there were 20 RL and
58 NRL
Index Threshold (number rated
NRL-number rated RL)
Sensitivity Specificity NPV PPV Accuracy
Using cutoff threshold of 15 %
ΔSUVmax_BW 15 % (35-43) 80 % 53 % 89 % 37 % 60 %
ΔSUV40 %_BW 15 % (32-46) 95 % 53 % 97 % 41 % 64 %
ΔSUVmax_BSA 15 % (35-43) 80 % 53 % 89 % 37 % 60 %
ΔSUV40 %_BSA 15 % (33-45) 95 % 55 % 97 % 42 % 65 %
Using cutoff threshold of 25 %
ΔSUVmax_BW 25 % (46-32) 65 % 67 % 85 % 41 % 67 %
ΔSUV40 %_BW 25 % (39-39) 90 % 64 % 95 % 46 % 71 %
ΔSUVmax_BSA 25 % (46-32) 65 % 67 % 85 % 41 % 67 %
ΔSUV40 %_BSA 25 % (39-39) 90 % 64 % 95 % 46 % 71 %
Aiming at a 95 % sensitivity of detection of RL
ΔSUVmax_BW 14 % (32-46) 95 % 53 % 97 % 41 % 64 %
ΔSUV40 %_BW 22 % (38-40) 95 % 64 % 97 % 47 % 72 %
diffSUVmax_BW 1.4 (33-45) 95 % 55 % 97 % 42 % 65 %
diffSUV40 %_BW 1.2 (41-37) 95 % 69 % 98 % 51 % 76 %
Aiming at a 95 % NPV for detection of RL
ΔSUVmax_BW 14 % (32-46) 95 % 53 % 97 % 41 % 64 %
ΔSUV40 %_BW 22 % (38-40) 95 % 64 % 97 % 47 % 72 %
diffSUVmax_BW 1.4 (33-45) 95 % 55 % 97 % 42 % 65 %
diffSUV40 %_BW 1.2 (41-37) 95 % 69 % 98 % 51 % 76 %
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could improve the identification of RL and NRL. Figure 1
and Table 1 suggest that absolute change and per cent
change convey about the same information for lesion
classification: the AUC obtained with the per cent
change were not significantly different from the AUC
obtained with the absolute change for a given X_Y combina-
tion (e.g. ΔSUVmax_BW against diffSUVmax_BW). The cutoff
threshold required to reach a 95 % sensitivity of detecting RL
was 1.4 (decrease of SUV by at least 1.4, Table 2) with
SUVmax_BW (specificity of 55 %, NPVof 97 %) and was 1.2
with SUV40 %_BW (specificity of 69%, NPVof 98%). Using a
threshold of 1.2 with SUVmax_BW leaves the sensitivity and
NPV almost unchanged (sensitivity of 95 % and NPV of
96 %), but decreased the specificity (40 %) and overall accu-
racy (54 %). Considering a threshold of 1.4 with SUV40 %_BW,
the sensitivity would be 85 % only (specificity of 74 %, NPV
of 93 %). The cutoff threshold is actually less dependent on
the way SUV is measured when expressed as an absolute
decrease in SUV (varying from 1.2 to 1.4 decline to reach a
sensitivity of 95 %, depending on whether one measures
SUV40 %_BW or SUVmax_BW) than when expressed as a per
cent change (varying between 14 and 22 % decline). Further
investigations including other tumour types and imaging pro-
tocols are needed to determine whether relying on absolute
decrease of SUV instead of per cent decrease could make the
threshold less dependent on the way SUVismeasured. Table 2
also demonstrates that when setting the sensitivity or NPV to
95 %, diffSUV40 %_BW had the highest accuracy compared
with all other measured changes.
Table 2 shows that the cutoff threshold did not depend on
the way SUV was normalized. This lack of difference is due
to the very high correlation between the ΔSUVX_BW and
ΔSUVX_BSA values (r
2>0.99) or between diffSUVX_BWand
diffSUVX_BSA (r
2>0.98). As a result, when using early PET
for patient monitoring, SUV can be calculated by normaliz-
ing either by the BSA or by the BW. Although EORTC
recommended the use of BSA for normalization, most
centres actually use BW for convenience. Our results
suggest that this does not make a difference and that the
thresholds recommended by the EORTC when considering
BSA as a normalizing factor are still valid when using BW
instead. This conclusion is only valid in case of early treat-
ment response evaluations, which are often performed at
one course of chemotherapy before major changes in body
tissue composition occur (i.e. loss of the non-FDG-avid fat
compartment).
It has been suggested that “the 15 % decline in SUV in
the original EORTC criteria for early response is probably
too modest to reliably be discerned from variability in the
study and likely is insufficient to be medically relevant
based on data developed since that time” [8]. Our results
did not confirm this statement and demonstrated that using a
14 % decline in SUVmax was appropriate to identify RL with
a sensitivity of 95 %.
One of the major observations of the study was that when
applying the optimal cutoffs for treatment response in terms
of sensitivity (aiming at 95 %) the specificities and positive
predictive values were low (ranging from 53 to 69 % and 41
to 51 %, respectively). The understanding of this is that an
early metabolic response does not always translate to a
significant reduction of size later on (i.e. 30 % according
to RECIST). This could indicate that in some lesions the
metabolic response is transient and short lasting or that the
size criteria which are used as the reference in this study are
not sensitive enough to detect response. Differentiation of
these would need a true reference of response, based on
tissue analysis of one or more target lesions via biopsy,
which was not performed in the current study.
Our results were obtained for a specific cohort of patients
and monitoring protocol. Given that in our patients most
lesions were liver metastases (49 of 78 lesions), all analyses
were also systematically performed by including only the 49
liver metastases (16 RL and 33 NRL according to RECIST
1.0) (results not shown). No significant differences were
found compared to the results obtained when including all
lesions, and all conclusions drawn from the studies includ-
ing all lesions were identical when restricting the analysis to
the liver metastases. Whether the recommended thresholds
are also valid for other types of tumours, other treatment
modalities and other monitoring protocols remains to be
investigated. The translation of the current lesion-by-lesion
analysis data into a patient-based response classification
using treatment outcome measures such as time to progres-
sion and/or overall survival has been recently reported by
Hendlisz et al. [16].
In this paper, early response was evaluated using acquisi-
tion and analysis protocols frequently used in nuclear medi-
cine departments. Yet, more sophisticated protocols or
analysis methods are also being investigated for the evaluation
of early response, including the use of dynamic protocols
allowing for calculation of kinetic parameters, or of parametric










SUVmax_BW RL 27 5
NRL 12 34
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imaging methods (e.g. [17–19]). Such approaches show
promise for improved assessment of early response and might
outperform more conventional data analysis.
Conclusion
Using a prospective cohort of 28 patients with metastatic
colorectal cancer (78 target lesions in total), we showed that
the SUV cutoff thresholds recommended by the EORTC to
identify tumours responding to therapy yielded high sensitivity
and NPV for detecting tumour response after a single course of
polychemotherapy. However, the sensitivity obtained when
using the recommended 15 % decrease in SUV to identify a
tumour response after one cycle of chemotherapy varied from
80% forΔSUVmax (specificity of 53%, NPVof 89%) to 95%
for ΔSUV40 % (specificity of 53 %, NPVof 97 %). Defining
the threshold as an absolute SUV decrease instead of a per cent
change made the threshold less sensitive to the SUV definition:
an SUV decline by 1.2 yielded a sensitivity of 95 % for
SUVmax and SUV40 %. For a given cutoff threshold, the
sensitivity was the same regardless of whether SUV was
normalized by BSA or by BW.
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